Aspirin 324 mg - search results

United States - English - NLM (National Library of Medicine)

aspirin- aspirin tablet, film coated

cardinal health, inc. - aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e) - aspirin 325 mg - pain reliever temporarily relieves - headache - muscle pain - toothache - menstrual pain - pain and fever of colds - minor pain of arthritis do not use if you are allergic to aspirin or any other pain reliever/fever reducer. stop use and ask a doctor if - an allergic reaction occurs. seek medical help right away. - you experience any of the following signs of stomach bleeding: •feel faint •have bloody or black stools •vomit blood •have stomach pain that does not get better - new symptoms occur - pain gets worse or lasts more than 10 days - redness or swelling is present - fever lasts more than 3 days - ringing in the ears or a loss of hearing occurs

United States - English - NLM (National Library of Medicine)

aspirin-dipyridamole capsule

zydus lifesciences limited - aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e), dipyridamole (unii: 64alc7f90c) (dipyridamole - unii:64alc7f90c) - aspirin 25 mg - aspirin and extended-release dipyridamole capsules are indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. aspirin and extended-release dipyridamole capsules are contraindicated in patients with known hypersensitivity to any of the product components. aspirin is contraindicated in patients with known allergy to nonsteroidal anti-inflammatory drug (nsaid) products and in patients with the syndrome of asthma, rhinitis, and nasal polyps. aspirin may cause severe urticaria, angioedema or bronchospasm. do not use aspirin in children or teenagers with viral infections because of the risk of reye syndrome. risk summary available data from published studies and postmarketing experience with aspirin and extended-release dipyridamole capsule use during pregnancy have not identified a clear association between aspirin and extended-release dipyridamole capsule use and major birth defects, miscarriage, or adverse maternal or fetal

United States - English - NLM (National Library of Medicine)

aspirin-dipyridamole capsule

zydus pharmaceuticals usa inc. - aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e), dipyridamole (unii: 64alc7f90c) (dipyridamole - unii:64alc7f90c) - aspirin 25 mg - aspirin and extended-release dipyridamole capsules are indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. aspirin and extended-release dipyridamole capsules are contraindicated in patients with known hypersensitivity to any of the product components. aspirin is contraindicated in patients with known allergy to nonsteroidal anti-inflammatory drug (nsaid) products and in patients with the syndrome of asthma, rhinitis, and nasal polyps. aspirin may cause severe urticaria, angioedema or bronchospasm. do not use aspirin in children or teenagers with viral infections because of the risk of reye syndrome. risk summary available data from published studies and postmarketing experience with aspirin and extended-release dipyridamole capsule use during pregnancy have not identified a clear association between aspirin and extended-release dipyridamole capsule use and major birth defects, miscarriage, or adverse maternal or fetal

Australia - English - Department of Health (Therapeutic Goods Administration)

apo-clopidogrel/aspirin 75/75 clopidogrel (as hydrogen sulfate)/aspirin 75 mg/75 mg tablet bottle

arrotex pharmaceuticals pty ltd - clopidogrel hydrogen sulfate, quantity: 97.88 mg; aspirin, quantity: 75 mg - tablet, film coated - excipient ingredients: hyprolose; titanium dioxide; iron oxide yellow; zinc stearate; maize starch; microcrystalline cellulose; crospovidone; methylcellulose; hypromellose; lactose; colloidal anhydrous silica; macrogol 8000 - clopidogrel/aspirin is a fixed dose combination product. clopidogrel/aspirin is intended as continuation of therapy in patients with acute coronary syndrome already initiated with separate clopidogrel and aspirin products:,? unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). clopidogrel/aspirin is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent).,? st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, clopidogrel/aspirin has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.